BillionToOne

BillionToOne is ranked at the top 5% of Y Combinator companies with close to $400M in funding. In June 2024, we closed a $130M Series D resulting in a company valuation of over $1 billion. This funding has come from prestigious global institutional investors, including Hummingbird, Adams Street Partners, Neuberger Berman, Baillie Gifford, and Premji Invest. We have developed a DNA molecular counter that increases cfDNA diagnostic resolution by over 1,000x. Our first product, Unity, is the first and only non-invasive prenatal test that can directly screen an unborn baby and assess its risk for: common and severe recessive gene disorders; chromosomal abnormalities; fetal sex; and fetal antigens from a single tube of blood from the pregnant mother. This greatly improves the quality of care and is on its path to becoming the next standard-of-care. Our software stack includes Python/Django, React/Typescript, Terraform, AWS, and many other standard tools. We’re a small, but nimble software team that prioritizes rapid iteration and continuous feedback to evolve our product. As a biotech company, we inherently need to always work cross functionally. If you enjoy this style of work, please reach out!